O
VTGN icon

OrbiMed’s VistaGen Therapeutics VTGN Stock Holding History

OrbiMed’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,060,000
Closed -$1.75M – 150
2026
Q1 		$1.75M Hold
3,060,000
– – 0.03% 109
2025
Q4 		$2.03M Hold
3,060,000
– – 0.04% 100
2025
Q3 		$10.9M Buy
+3,060,000
New +$9.14M 0.26% 73
2022
Q3 		– Sell
-447,376
Closed -$11.8M – 147
2022
Q2 		$11.8M Buy
447,376
+17,067
+4% +$603K 0.21% 84
2022
Q1 		$16M Hold
430,309
– – 0.26% 77
2021
Q4 		$25.2M Hold
430,309
– – 0.32% 75
2021
Q3 		$35.4M Sell
430,309
-51,953
-11% -$4.51M 0.39% 70
2021
Q2 		$45.6M Buy
482,262
+195,462
+68% +$14.5M 0.46% 61
2021
Q1 		$18.3M Buy
286,800
+36,800
+15% +$2.46M 0.17% 103
2020
Q4 		$14.6M Buy
+250,000
New +$6.38M 0.13% 113

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

OrbiMed's VTGN Position: Q2 2026 in Review

OrbiMed sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 3,060,000 shares — an estimated $1.75M sold.

OrbiMed first reported a position in VTGN in Q4 2020 and held it in 10 quarters. The position peaked at $45.6M in Q2 2021. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • OrbiMed reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OrbiMed sold 3,060,000 VistaGen Therapeutics shares in Q2 2026, an estimated $1.75M.
  • OrbiMed first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 10 quarters.
  • OrbiMed's VistaGen Therapeutics position peaked at $45.6M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.